GlassScriptPhysician profile
Golam Daud Noaz
NPI 1679816235
$5,154.04
in general payments reported to CMS, 2019-2025
35 companies · $808 in 2025
The $808 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $484 · 2021: $400 · 2022: $832 · 2023: $1,036 · 2024: $1,072 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,916.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $477.99 | 2019-2025 | Breztri, Farxiga, Fasenra |
| Novo Nordisk INC | $464.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $410.13 | 2019-2025 | Jardiance, Ofev, Tradjenta |
| Amgen INC. | $398.18 | 2019-2024 | Repatha, Otezla, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $347.99 | 2023-2025 | |
| Pfizer INC. | $317.37 | 2019-2025 | |
| Glaxosmithkline, LLC. | $296.95 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $277.10 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $256.93 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $250.87 | 2020-2025 | Xifaxan, Trulance |
| Ucb, INC. | $238.10 | 2023-2025 | Briviact, Nayzilam |
| Dexcom, INC. | $168.25 | 2022-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $157.57 | 2020-2025 | Spravato |
| Astellas Pharma US INC | $139.31 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $136.79 | 2019-2023 | Austedo Xr, Austedo |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Golam Noaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.